Viking Therapeutics, Inc. (VKTX) Form 8-K — Oct 28, 2026
Viking Therapeutics reported a Q3 2026 net loss of $183.2 million ($1.55 per share), roughly double the $90.8 million loss a year earlier, driven by R&D spending that rose to $166.8 million from $90.0 million as Phase 3 obesity trials ramp up. The pipeline advanced on multiple fronts: the SUNRISE Phase 3 program for oral VK2735 is underway (third and fourth registration trials), Part 1 of the VK2735 maintenance study showed 82-97% weight-loss retention on less-frequent dosing, and the Phase 1 amylin agonist VK3019 SAD study is nearing completion.
Key figures
- Revenue
- 0
- Guidance
- VANQUISH Phase 3 studies expected to complete in 2027; extension study results in 2028; VK3019 SAD study completing in Q4 2026 with MAD study in 1Q27; Part 2 maintenance study results in 2027.
- Total Debt
- 250656000
- Total Assets
- 977167000
- Cash Position
- 960000000
- Shares Outstanding
- 127521229
- Q3 ga expense
- 20300000
- Q3 r d expense
- 166800000
- Cash dec 31 2025
- 706000000
- Nine month net loss
- 469500000
- Vanquish1 enrollment
- 4500
- Vanquish2 enrollment
- 1000
- Financing net proceeds
- 550000000
- Q3 net loss prior year
- 90800000
- Financing gross proceeds
- 575000000
- Q3 ga expense prior year
- 8600000
- Q3 r d expense prior year
- 90000000
- Sunrise enrollment target each
- 560
- Exploratory week33 weight loss pct
- 22
- Maintenance week21 weight loss range pct
- 16-19
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.